Terms ending in 2027
Bayer Pharma Aktiengesellschaft
Every in-force patent on Bayer Pharma Aktiengesellschaft's record whose computed term ends in 2027, whoever holds it now. Soonest term end first, then patent number.
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 7,718,640 | Methods and Pharmaceutical Compositions for Reliable Achievement of Acceptable Serum Testosterone Levels In force · High confidence | Grünenthal GmbH | In force | High confidence | |
| US 8,324,412 | Method for Preparing 4-[17BETA-METHOXY-17ALPHA-METHOXYMETHYL-3-Oxoestra-4,9-DIEN-11-BETA-YL]BENZALDEHYDE (E)-Oxime (ASOPRISNIL) In force · High confidence | Bayer Intellectual Property GmbH | In force | High confidence | |
| US 8,338,395 | Methods and Pharmaceutical Compositions for Reliable Achievement of Acceptable Serum Testosterone Levels In force · High confidence | Grünenthal GmbH | In force | High confidence | |
| US 7,932,278 | 2-Aminoethoxyacetic Acid Derivatives and Their Use In force · High confidence | Bayer Intellectual Property GmbH | In force | High confidence | |
| US 8,987,261 | Substituted Dihydropyrazolones for Treating Cardiovascular and Hematological Diseases In force · Medium confidence | Bayer Pharma Aktiengesellschaft | In force | Medium confidence | |
| US 8,049,035 | Crystalline Potassium Salt of Lipoxin A4 Analogs In force · High confidence | The Brigham and Women's Hospital, Inc. | In force | High confidence |
6 of 6 patents shown. Soonest term end first, then patent number.
1 of these is in force and held by Bayer Pharma Aktiengesellschaft.
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.